Baxter International Inc
BAX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$72.00 | Xxvbnh | Cvprlyy |
Baxter Delivers Strong Q3 With Higher-Than-Expected Margins; No FVE Change
Baxter reported strong third-quarter results, including higher margins than we were expecting. Even after mildly increasingly our near-term profit assumptions, though, our $86 fair value estimate has not changed materially. We continue to view Baxter's moat as narrow and built on its essential dialysis and injectable therapies, which have both intangible assets and switching costs as moat sources.